MEDIA CENTER


Our online resource featuring the
latest news about our company.

RECENT NEWS, BLOGS AND ARTICLES

Press Release

Press Release | 

February 28, 2025

The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease

Read more >

Blog

Blog | 

January 31, 2025

Spotlighting What Makes Eisai Oncology Unique this World Cancer Day

Read more >

Press Release

Press Release | 

January 26, 2025

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease

Read more >

Press Release

Press Release | 

January 24, 2025

Merck and Eisai Provide Update on Phase 3 LEAP-015 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination with Chemotherapy in Patients with Certain Types of Gastroesophageal Adenocarcinoma

Read more >

explore all articles
explore all articles
explore all blogs
explore all blogs
explore all press releases
explore all press releases

MEDIA
RESOURCES

CORPORATE FACT SHEET

Learn more about Eisai Inc.

Go to Fact Sheet

EXTON
FACT SHEET

Learn about our Exton, PA campus

Go to Fact Sheet

MULTIMEDIA RESOURCES

Find digital assets (logos and images) for Eisai

Go to Resources

CONTACT INFORMATION

For media inquiries, please contact:

CORPORATE

Patricia Councill
Director, Corporate Communications
551-262-2686
Patricia_Councill@eisai.com

NEUROLOGY

Libby Holman
Senior Director, Product Communications
201-753-1945
Libby_Holman@eisai.com

ONCOLOGY

Michele Randazzo
Senior Director, Product Communications
201-248-2228
Michele_Randazzo@eisai.com

INVESTORS

For current investors or those interested in becoming investors, please click below to be connected with the global Eisai Investor page.

investor info
investor info

SOCIAL MEDIA

Stay up to date on everything Eisai.

Find us on @EisaiUS External link icon

Find us on @Eisai Linkedin logo